HYPAQUE by GE HealthCare is clinical pharmacology retrograde introduction of hypaque-cysto solution provides radiopacity of the contents of the urinary bladder. First approved in 1954.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
HYPAQUE is a water-soluble iodinated contrast medium (diatrizoate meglumine) administered via retrograde injection into the urinary bladder for radiographic visualization during cystourethrography procedures. It provides radiopacity to enable detection of cystoureteric reflux and assessment of bladder and lower urinary tract function during micturition studies. The agent is not absorbed systemically from the urinary tract but carries risk of adverse effects if inadvertent intravascular entry occurs.
Approaching loss of exclusivity with moderate competitive pressure (30/100) signals potential team restructuring and transition planning for brand professionals.
CLINICAL PHARMACOLOGY Retrograde introduction of HYPAQUE-CYSTO solution provides radiopacity of the contents of the urinary bladder. When used during micturation as a function test, it also opacifies the bladder neck and lower urinary tract. Continuous fluoroscopic and monitoring of urinary bladder…
Worked on HYPAQUE at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
HYPAQUE positions career professionals in lifecycle management, cost containment, and operational efficiency roles rather than growth-oriented functions. Working on this product provides experience in mature asset stewardship and LOE transition strategy within a specialty diagnostic market.